B cell immunobiology in disease: Evolving concepts from the clinic

被引:268
作者
Martin, Flavius [1 ]
Chan, Andrew C.
机构
[1] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA
关键词
CD20; Rituxan; BAFF/BLyS; BR3;
D O I
10.1146/annurev.immunol.24.021605.090517
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The pathogenic roles of B cells in autoimmune diseases occur through several mechanistic pathways that include autoantibodies, immune complexes, dendritic and T cell activation, cytokine synthesis, chemokine-mediated functions, and ectopic neolymphogenesis. Each of these pathways participate to different degrees in autoimmune diseases. The use of B cell-targeted and B cell subset-targeted therapies in humans is illuminating the mechanisms at work in a variety of human autoimmune diseases. In this review, we highlight some of these recent findings that provide insights into both murine models of autoimmunity and human autoimmune diseases.
引用
收藏
页码:467 / 496
页数:30
相关论文
共 184 条
[81]   Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis [J].
Keogh, KA ;
Wylam, ME ;
Stone, JH ;
Specks, U .
ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :262-268
[82]   Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice [J].
Khare, SD ;
Sarosi, I ;
Xia, XZ ;
McCabe, S ;
Miner, K ;
Solovyev, I ;
Hawkins, N ;
Kelley, M ;
Chang, D ;
Van, G ;
Ross, L ;
Delaney, J ;
Wang, L ;
Lacey, D ;
Boyle, WJ ;
Hsu, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3370-3375
[83]   CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain [J].
Koyama, M ;
Ishihara, K ;
Karasuyama, H ;
Cordell, JL ;
Iwamoto, A ;
Nakamura, T .
INTERNATIONAL IMMUNOLOGY, 1997, 9 (11) :1767-1772
[84]  
Krzysiek R, 1999, J IMMUNOL, V162, P4455
[85]   Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome [J].
Lavie, F ;
Miceli-Richard, C ;
Quillard, J ;
Roux, S ;
Leclerc, P ;
Mariette, X .
JOURNAL OF PATHOLOGY, 2004, 202 (04) :496-502
[86]   An open study of B lymphocyte depletion in systemic lupus erythematosus [J].
Leandro, MJ ;
Edwards, JC ;
Cambridge, G ;
Ehrenstein, MR ;
Isenberg, DA .
ARTHRITIS AND RHEUMATISM, 2002, 46 (10) :2673-2677
[87]   Rituxan in the treatment of cold agglutinin disease [J].
Lee, EJ ;
Kueck, B .
BLOOD, 1998, 92 (09) :3490-3491
[88]   Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma [J].
Leonard, JP ;
Coleman, M ;
Ketas, JC ;
Chadburn, A ;
Ely, S ;
Furman, RR ;
Wegener, WA ;
Hansen, HJ ;
Ziccardi, H ;
Eschenberg, M ;
Gayko, U ;
Cesano, A ;
Goldenberg, DM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3051-3059
[89]   Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF [J].
Lesley, R ;
Xu, Y ;
Kalled, SL ;
Hess, DM ;
Schwab, SR ;
Shu, HB ;
Cyster, JG .
IMMUNITY, 2004, 20 (04) :441-453
[90]   IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab [J].
Levine, TD ;
Pestronk, A .
NEUROLOGY, 1999, 52 (08) :1701-1704